ONC (BeOne Medicines) Float Percentage Of Total Shares Outstanding: 68.42% (As of Jun. 30, 2026)


ONC BeOne Medicines Ltd ONC
81 GF Score
Price $284.97
GF Value $366.06
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is BeOne Medicines Float Percentage Of Total Shares Outstanding?

BeOne Medicines ONC -1.73% 81 Float Percentage Of Total Shares Outstanding is 68.42% as of Jun. 30, 2026. GuruFocus rates ONC with a GF Score™ of 81/100 and a GF Value™ of $366.06 (Modestly Undervalued). The stock has 4 warning signs investors should review.

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, BeOne Medicines's float shares is 70.99 Mil. BeOne Medicines's total shares outstanding is 103.75 Mil. BeOne Medicines's float percentage of total shares outstanding is 68.42%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, BeOne Medicines's Insider Ownership is 1.10%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, BeOne Medicines's Institutional Ownership is 31.32%.

ONC
81GF Score
BeOne Medicines Ltd ONC
Float Percentage Of Total Shares Outstanding is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BeOne Medicines Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

BeOne Medicines's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=70.99/103.75
=68.42%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Float Percentage Of Total Shares Outstanding of 68.42% mean?
BeOne Medicines (ONC) has a Float Percentage Of Total Shares Outstanding of 68.42% as of Jun. 30, 2026. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on BeOne Medicines and its competitors.
Is BeOne Medicines' Float Percentage Of Total Shares Outstanding too high?
BeOne Medicines' current Float Percentage Of Total Shares Outstanding is 68.42%. Overall, BeOne Medicines has a GF Score™ of 81/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BeOne Medicines' Float Percentage Of Total Shares Outstanding compare to MRNA and RPRX?
BeOne Medicines' Float Percentage Of Total Shares Outstanding of 68.42% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Float Percentage Of Total Shares Outstanding for a Biotechnology company?
A good Float Percentage Of Total Shares Outstanding depends on the Biotechnology industry context. However, Float Percentage Of Total Shares Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Float Percentage Of Total Shares Outstanding mean?
A high Float Percentage Of Total Shares Outstanding can signal that a stock is expensive relative to its fundamentals. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on BeOne Medicines and its competitors. BeOne Medicines's current Float Percentage Of Total Shares Outstanding is 68.42%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BeOne Medicines stock overvalued right now?
Based on GuruFocus' analysis, BeOne Medicines (ONC) is currently considered Modestly Undervalued. The stock's GF Value™ is $366.06, compared to a current price of $284.97 — trading 22.2% below its estimated fair value. The current Float Percentage Of Total Shares Outstanding is 68.42%. BeOne Medicines' overall GF Score™ is 81/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Float Percentage Of Total Shares Outstanding calculated?
Float Percentage Of Total Shares Outstanding is calculated from a company's financial statements. For BeOne Medicines (ONC), the current Float Percentage Of Total Shares Outstanding is 68.42% as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BeOne Medicines (ONC) Overvalued in 2026?

Based on GuruFocus' analysis, BeOne Medicines stock appears to be undervalued. The current stock price of $284.97 is trading 22.2% below its estimated GF Value™ of $366.06. GuruFocus considers BeOne Medicines to be Modestly Undervalued.

Key valuation signals for ONC:

  • Float Percentage Of Total Shares Outstanding: 68.42%
  • GF Value™: $366.06 vs. price of $284.97 (22.2% below fair value)
  • GF Score™: 81/100 with 4 warning signs

No single metric tells the full story. See the ONC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BeOne Medicines Business Description

Address c/o BeOne Medicines I GmbH, 94 Aeschengraben 27, 21st Floor, Basel, CHE, 4051
Formerly known as BeiGene and founded in 2010 in Beijing, BeOne is a commercial-stage biotech firm that produces oncology therapeutics. The company's main product is Brukinsa, which is a small-molecule drug that treats multiple forms of Non-Hodgkin lymphoma and leukemia. The company conducts drug discovery, runs global clinical trials, and manufactures drugs independently. As of 2025, Brukinsa made up for 74% of total revenue, while it has two other approved commercialized drugs in its portfolio, Beqalzi and Tevimbra. While Brukinsa has a global leadership, the other two drugs generate revenue mostly from China. Based on Brukinsa, BeOne competes with AbbVie and AstraZeneca mainly. The company also has more than 50 drugs in clinical trials in its active pipeline, focused on other cancers.
81GF Score

Get the complete analysis for ONC

Float Percentage Of Total Shares Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$284.97
Price
$366.06
GF Value